Xfin 1%

Description

• Indications:

  • Xfin Tablet: Treatment of onychomycosis (nail infection) due to dermatophytes.
  • Xfin Granules: Treatment of Tinea Capitis (scalp fungal infection).
  • Xfin Cream: Treatment for skin fungal infections caused by Trichophyton, Microsporum, Epidermophyton, and yeast infections (Candida).
  • Xfin 1% Spray: Treatment for tinea skin infections and pityriasis versicolor (Malassezia furfur).

• Pharmacology: Terbinafine, the active ingredient, inhibits ergosterol biosynthesis, leading to fungal cell death by increasing membrane permeability. It is fungicidal to many strains like Trichophyton rubrum.

• Dosage & Administration:

  • Tablets:
    • Fingernail onychomycosis: 250 mg daily for 6 weeks.
    • Toenail onychomycosis: 250 mg daily for 12 weeks.
  • Granules:
    • <25 kg: 125 mg daily for up to 6 weeks.
    • 25-35 kg: 187.5 mg daily for up to 6 weeks.

    • 35 kg: 250 mg daily for up to 6 weeks.

  • Cream: Apply once or twice daily for 1-2 weeks depending on the infection type.
  • Spray: Apply once or twice daily for 1 week, depending on the condition.

• Interactions: Terbinafine inhibits CYP450 2D6 enzymes, which may interact with certain drugs like antidepressants, beta-blockers, and antiarrhythmics.

• Contraindications: Hypersensitivity to terbinafine and pre-existing liver conditions.

• Side Effects: Common side effects include gastrointestinal disturbances, rashes, and liver test abnormalities. Serious side effects can include liver failure and severe skin reactions.

• Pregnancy & Lactation:

  • Tablets: Not recommended during pregnancy or breastfeeding due to potential risks.
  • Cream: Should be used cautiously during pregnancy; not recommended during breastfeeding.

• Precautions: Regular liver monitoring is advised during treatment, especially for those with liver disease. The cream is for external use only, and contact with eyes should be avoided.

• Storage: Store in a cool, dry place below 30°C and protect from light.